Review
Biochemistry & Molecular Biology
Sindhu Nair, James A. Bonner, Markus Bredel
Summary: EGFR is overexpressed in head and neck squamous cell carcinoma and anti-EGFR strategies have shown some clinical benefit but often lead to resistance. Mutations in various domains of the EGFR gene can impact drug binding, radiation response, and overall survival in HNSCC patients. Understanding the EGFR mutational landscape and its effects on treatment resistance can help stratify patients for targeted therapies and maximize therapeutic benefits.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Xin Zhou, Xiaoshen Wang
Summary: This review provides a detailed illustration of the biology, genomic features, and immune landscapes of HPV-associated HNSCC, supporting the synergistic effect of radioimmunotherapy. Current evidence and ongoing clinical trials suggest the potential of radioimmunotherapy in recurrent/metastatic or definitive settings. Future challenges include optimization of radiotherapy and the incorporation of novel therapeutic options.
Review
Medicine, General & Internal
Kamila Romanowska, Agnieszka Sobecka, Agnieszka A. Rawluszko-Wieczorek, Wiktoria M. Suchorska, Wojciech Golusinski
Summary: Head and neck squamous carcinoma (HNSCC) is the sixth most prevalent cancer worldwide, with molecular pathogenesis involving cell cycle disorders, intercellular signaling, proliferation, squamous cell differentiation, and apoptosis. In addition to genetic mutations, epigenetic alterations such as DNA methylation and histone modifications play a key role in promoting cancer formation and progression, making them potential biomarkers and therapeutic targets for HNSCC.
Article
Medicine, General & Internal
Erdem Yildiz, Stefan Grasl, Doris-Maria Denk-Linnert, Gabriela Altorjai, Harald Herrmann, Matthaeus C. Grasl, Boban M. Erovic, Stefan Janik
Summary: This study evaluated the impact of radiotherapy on dysphagia and long-term swallowing outcome in patients with head and neck squamous cell carcinomas. The results showed that nearly all patients complained about dysphagia at the end of radiotherapy, but it significantly improved over time.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, Research & Experimental
Vaishali Chandel, Saurabh Maru, Arun Kumar, Ashok Kumar, Ashok Sharma, Brijesh Rathi, Dhruv Kumar
Summary: Head and Neck tumors exhibit highly altered metabolism, with cancer cells utilizing different pathways for energy production. Monocarboxylate transporters play a crucial role in regulating lactate and maintaining pH balance, essential for cancer cell survival and growth control.
Article
Oncology
Zongtai Qi, Yating Liu, Michael Mints, Riley Mullins, Reilly Sample, Travis Law, Thomas Barrett, Angela L. Mazul, Ryan S. Jackson, Stephen Y. Kang, Patrik Pipkorn, Anuraag S. Parikh, Itay Tirosh, Joseph Dougherty, Sidharth V. Puram
Summary: Tumors are composed of diverse cells rather than a uniform ball of cells. Recent studies have shown that deconvolution algorithms can be used to computationally estimate cell-type proportions from gene expression data, although their performance in tumor tissues remains unclear.
Review
Biochemistry & Molecular Biology
Ching-Yun Hsieh, Ching-Chan Lin, Wei-Chao Chang
Summary: Taxanes, especially docetaxel, are widely used in combination therapy for head and neck squamous cell carcinoma (HNSCC) and have shown advantages in improving patient outcomes. Taxanes not only function as antimitotics, but also impair various oncogenic signaling pathways. However, the development of drug resistance remains a major obstacle to treatment response.
Article
Cell Biology
Julia Ingruber, Dragana Savic, Teresa Bernadette Steinbichler, Susanne Sprung, Felix Fleischer, Rudolf Glueckert, Gabriele Schweigl, Ira-Ida Skvortsova, Herbert Riechelmann, Jozsef Dudas
Summary: The study found that in head and neck squamous cell carcinoma, Slug gene expression was significantly higher while KLF4 gene expression was significantly lower. There was a significant negative correlation between KLF4 and Slug gene expression in the majority of HNSCC samples. TGF-β1 contributed to the downregulation of KLF4 and the upregulation of Slug.
Review
Biochemistry & Molecular Biology
Shengjian Jin, Yasusei Kudo, Taigo Horiguchi
Summary: Ubiquitination and deubiquitination are two common post-translational modifications of proteins, affecting their intracellular localization, stability, and function. Deubiquitination is involved in various cellular processes, including histone modification, cell cycle regulation, apoptosis, and cancer development. This review focuses on the understanding of the function of deubiquitinating enzymes in head and neck squamous cell carcinoma (HNSCC) and discusses potential therapeutic strategies for HNSCC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Cell Biology
Chenhang Yu, Qiang Li, Yu Zhang, Zhi-Fa Wen, Heng Dong, Yongbin Mou
Summary: Head and neck squamous cell carcinoma (HNSCC) has a high incidence and mortality rate. Immunotherapy, with its potential for a broad and long-lasting antitumor response, has become an important therapeutic strategy for HNSCC. However, immune escape limits the effectiveness of immunotherapy. Various immunotherapy strategies, including immune checkpoint inhibitors, costimulatory agonists, antigenic vaccines, oncolytic virus therapy, adoptive T cell transfer, and targeted therapy, have been developed for HNSCC. Each strategy has its unique advantages, and their appropriate application has significant value for the treatment of HNSCC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Oncology
Ruoyan Cao, Lin Cui, Jiayu Zhang, Xianyue Ren, Bin Cheng, Juan Xia
Summary: This study identifies subtypes of head and neck squamous cell carcinoma based on immune-related lncRNAs and characterizes their biological behaviors. The researchers found that certain subtypes are associated with good prognosis and sensitivity to immunotherapy, and identified a critical lncRNA TRG-AS1 involved in the tumor microenvironment. This provides new potential targets for the treatment of this subtype.
CANCER CELL INTERNATIONAL
(2022)
Review
Oncology
Kainan Wu, Fen Chang, Wenming Li, Tongdong Su, Dapeng Lei
Summary: IGF2BPs are RNA-bound proteins that play a crucial part in various cell functions and act as members of the m6A reader family. They are particularly important in tumor metabolism, specifically in head and neck squamous cell carcinoma.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pathology
Gianluca Businello, Matteo Fassan, Silvia Degasperi, Giulia Traverso, Melania Scarpa, Imerio Angriman, Andromachi Kotsafti, Ignazio Castagliuolo, Marta Sbaraglia, Romeo Bardini, Marco Scarpa
Summary: The study suggests that HPV infection is not a factor associated with esophageal squamous cell carcinoma (ESCC) after head and neck squamous cell carcinoma (HNSCC). Instead, p53 overexpression is common in HNSCC-associated ESCCs. The altered immune microenvironment, characterized by dysregulated lymphomonocytic infiltration, may play a crucial role in the development of metachronous ESCC.
PATHOLOGY RESEARCH AND PRACTICE
(2021)
Article
Oncology
Moran Amit, Chuan Liu, Jobran Mansour, Frederico O. Gleber-Netto, Samantha Tam, Erez N. Baruch, Mohamed Aashiq, Adel K. El-Naggar, Amy C. Moreno, David I. Rosenthal, Bonnie S. Glisson, Renata Ferrarotto, Michael K. Wong, Kenneth Tsai, Elsa R. Flores, Michael R. Migden, Deborah A. Silverman, Goujun Li, Anshu Khanna, Ryan P. Goepfert, Priyadharsini Nagarajan, Randal S. Weber, Jeffrey N. Myers, Neil D. Gross
Summary: The study showed that elective neck dissection (END) did not improve survival rates for patients with cutaneous squamous cell carcinoma (cSCC) of the head and neck and no evidence of regional metastasis. Further research is needed to clarify the role of END in patients with advanced disease.
Review
Oncology
Xiao Han, Ruxian Tian, Cai Wang, Yumei Li, Xicheng Song
Summary: This review systematically summarizes the regulatory mechanisms of circular RNA (CircRNA) in head and neck squamous cell carcinoma (HNSCC), and explores its functions in tumor growth, cell death, angiogenesis, invasion, and metastasis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Ting Martin Ma, Yilun Sun, Shawn Malone, Mack Roach III, David Dearnaley, Thomas M. Pisansky, Felix Y. Feng, Howard M. Sandler, Jason A. Efstathiou, Isabel Syndikus, Emma C. Hall, Alison C. Tree, Matthew R. Sydes, Claire Cruickshank, Soumyajit Roy, Michel Bolla, Philippe Maingon, Theo De Reijke, Abdenour Nabid, Nathalie Carrier, Luis Souhami, Almudena Zapatero, Araceli Guerrero, Ana Alvarez, Carmen Gonzalez San-Segundo, Xavier Maldonado, Tahmineh Romero, Michael L. Steinberg, Luca F. Valle, Matthew B. Rettig, Nicholas G. Nickols, Jonathan E. Shoag, Robert E. Reiter, Nicholas G. Zaorsky, Angela Y. Jia, Jorge A. Garcia, Daniel E. Spratt, Amar U. Kishan
Summary: The sequencing of androgen-deprivation therapy (ADT) and radiotherapy (RT) may affect the outcome of prostate cancer depending on the size of the RT field. A study found that the sequencing of ADT has a significant impact on clinical outcomes for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT).
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Soumyajit Roy, Scott C. Morgan, Christopher J. D. Wallis, Yilun Sun, Daniel E. Spratt, Julia Malone, Scott Grimes, Dibya Mukherjee, Amar U. Kishan, Fred Saad, Shawn Malone
Summary: Pain is an important aspect of quality-of-life in mCSPC patients, but it is uncertain whether dynamic changes in pain over time can predict OS or rPFS. This study explores the association of dynamic changes in pain scores with OS and rPFS in mCSPC patients.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
Ziad Bakouny, Chris Labaki, Punita Grover, Joy Awosika, Shuchi Gulati, Chih-Yuan Hsu, Saif Alimohamed, Babar Bashir, Stephanie Berg, Mehmet A. Bilen, Daniel Bowles, Cecilia Castellano, Aakash Desai, Arielle Elkrief, Omar E. Eton, Leslie A. Fecher, Daniel Flora, Matthew D. Galsky, Margaret E. Gatti-Mays, Alicia Gesenhues, Michael J. Glover, Dharmesh Gopalakrishnan, Shilpa Gupta, Thorvardur R. Halfdanarson, Brandon Hayes-Lattin, Mohamed Hendawi, Emily Hsu, Clara Hwang, Roman Jandarov, Chinmay Jani, Douglas B. Johnson, Monika Joshi, Hina Khan, Shaheer A. Khan, Natalie Knox, Vadim S. Koshkin, Amit A. Kulkarni, Daniel H. Kwon, Sara Matar, Rana R. McKay, Sanjay Mishra, Feras A. Moria, Amanda Nizam, Nora L. Nock, Taylor K. Nonato, Justin Panasci, Lauren Pomerantz, Andrew J. Portuguese, Destie Provenzano, Matthew Puc, Yuan J. Rao, Terence D. Rhodes, Gregory J. Riely, Jacob J. Ripp, Andrea Rivera, Erika Ruiz-Garcia, Andrew L. Schmidt, Adam J. Schoenfeld, Gary K. Schwartz, Sumit A. Shah, Justin Shaya, Suki Subbiah, Lisa M. Tachiki, Matthew D. Tucker, Melissa Valdez-Reyes, Lisa B. Weissmann, Michael T. Wotman, Elizabeth M. Wulff-Burchfield, Zhuoer Xie, Yuanchu James Yang, Michael A. Thompson, Dimpy P. Shah, Jeremy L. Warner, Yu Shyr, Toni K. Choueiri, Trisha M. Wise-Draper
Summary: This cohort study found that systemic anticancer therapies, especially IO, in the context of baseline immunosuppression, were associated with severe clinical outcomes and the development of cytokine storm in patients with cancer and COVID-19.
Article
Urology & Nephrology
Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Mathew Smith, Christopher Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Vvww Daniel, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofmanfff, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek-Fossakkk, Robert Jonesmmm, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz, Christopher J. Logothetisp, Brandon A. Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hrioji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin
Summary: The voting results from the 2022 Advanced Prostate Cancer Consensus Conference provide valuable insights for clinical management in areas where high-level evidence is lacking. These results can guide physicians and patients in making treatment decisions and help prioritize future research.
Letter
Oncology
Cem Onal, Duygu Sezen, Ezgi Oymak, Yasemin Bolukbasi
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Review
Oncology
Simon K. B. Spohn, Cederic Draulans, Amar U. Kishan, Daniel Spratt, Ashley Ross, Tobias Maurer, Derya Tilki, Alejandro Berlin, Pierre Blanchard, Sean Collins, Peter Bronsert, Ronald Chen, Alan Dal Pra, Gert de Meerleer, Thomas Eade, Karin Haustermans, Tobias Holscher, Stefan Hocht, Pirus Ghadjar, Elai Davicioni, Matthias Heck, Linda G. W. Kerkmeijer, Simon Kirste, Nikolaos Tselis, Phuoc T. Tran, Michael Pinkawa, Pascal Pommier, Constantinos Deltas, Nina-Sophie Schmidt-Hegemann, Thomas Wiegel, Thomas Zilli, Alison C. Tree, Xuefeng Qiu, Vedang Murthy, Jonathan I. Epstein, Christian Graztke, Xin Gao, Anca L. Grosu, Sophia C. Kamran, Constantinos Zamboglou
Summary: Current risk-stratification systems for prostate cancer do not adequately reflect the disease heterogeneity. Genomic classifiers show promise in improving risk stratification after surgery, but limited data exist for patients treated with radiation therapy or in advanced stages of the disease. A systematic review and expert survey were conducted to evaluate the role of genomic classifiers in radiation therapy and identify future research areas for personalized treatment.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Paul L. Nguyen, Huei-Chung (Rebecca) Huang, Daniel E. Spratt, Elai Davicioni, Howard M. Sandler, William U. Shipley, Jason A. Efstathiou, Jeffry P. Simko, Alan Pollack, Adam P. Dicker, Mack Roach III, Seth A. Rosenthal, Kenneth L. Zeitzer, Lucas C. Mendez, Alan C. Hartford, William A. Hall, Anand B. Desai, Rachel A. Rabinovitch, Christopher A. Peters, Joseph P. Rodgers, Phuoc Tran, Felix Y. Feng
Summary: The study validates the performance of Decipher genomic classifier (GC) in pretreatment biopsy samples. The GC score is independently associated with distant metastases, prostate cancer-specific mortality, and overall survival, providing valuable prognostic information for personalized decision-making.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Eric M. Lander, Katherine C. Rappazzo, Li-Ching Huang, Jiun-Ruey Hu, Heidi Chen, Yu Shyr, Vandana G. Abramson
Summary: This novel study investigates the relationship between HER2 amplification and pathologic complete response (pCR) following neoadjuvant anti-HER2 dual therapy without chemotherapy. The results show a positive association between the HER2/CEP17 FISH ratio and pCR.
Article
Oncology
Adam B. B. Weiner, Yang Liu, Alex Hakansson, Xin Zhao, James A. A. Proudfoot, Julian Ho, J. J. H. H. Zhang, Eric V. V. Li, R. Jeffrey Karnes, Robert B. B. Den, Amar U. U. Kishan, Robert E. E. Reiter, Anis A. A. Hamid, Ashely E. E. Ross, Phuoc T. T. Tran, Elai Davicioni, Daniel E. E. Spratt, Gerhardt Attard, Tamara L. L. Lotan, Melvin Lee Kiang Chua, Christopher J. J. Sweeney, Edward M. M. Schaeffer
Summary: A prostate subtyping classifier (PSC) was created by analyzing expression profiles from over 100,000 prostate tumors, identifying four subtypes with distinct biological and clinical features.
Article
Oncology
Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Matthew Smith, Christopher J. Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De Santis, Ignacio Duran, Ross Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara A. Jereczek-Fossa, Rob Jones, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel J. Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hiroji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin
Summary: The APCCC 2022 addressed questions in various areas of advanced prostate cancer and provided voting results to supplement guidelines based on level 1 evidence. These results can assist clinicians, patients, research funders, and policy makers in making management decisions and identifying information gaps.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Urology & Nephrology
Soumyajit Roy, Yilun Sun, Scott C. Morgan, Christopher J. D. Wallis, Kevin King, Yu M. Zhou, Leah A. D'souza, Omar Azem, Adrianna E. Cueto-Marquez, Nathaniel B. Camden, Daniel E. Spratt, Amar U. Kishan, Fred Saad, Shawn Malone
Summary: This study investigated the influence of prior prostate-directed local therapy on first-line systemic therapy and survival in metastatic castrate-resistant prostate cancer (mCRPC) patients. The results showed that the efficacy and survival benefits of first-line abiraterone treatment did not significantly differ between patients who received prior local therapy and those who did not.
Article
Endocrinology & Metabolism
Soumyajit Roy, Christopher J. D. Wallis, Scott C. Morgan, Amar U. Kishan, Amy Tu Trinh Le, Julia Malone, Yilun Sun, Daniel E. Spratt, Fred Saad, Shawn Malone
Summary: This study analyzed the data from the ACIS study to determine if synchronous versus metachronous metastatic presentation is associated with survival and treatment response in docetaxel naive metastatic castrate resistant prostate cancer (mCRPC). The results showed that the stage of metastasis was not associated with disease progression, and there was no significant difference in the efficacy of treatment with docetaxel.
Article
Oncology
Ting Martin Ma, Felix Y. Feng, Seth A. Rosenthal, Matthew B. Rettig, Ann C. Raldow, Daniel E. Spratt, Michael Xiang, Amar U. Kishan
Summary: By comparing prostate cancer-specific mortality in patients from a real-world setting with those on a clinical trial, we found that trial patients had better outcomes, especially among Black patients, indicating significant racial disparities in the real world.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
Kristina Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott Boerner, Jing Li, Diane Durecki, Jan Drappatz, Vinay Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, S. Percy Ivy, Ranjit S. Bindra, Antonio Omuro, Patricia LoRusso
Summary: A multicenter study evaluated the efficacy of olaparib monotherapy in patients with IDH1/2-mutant gliomas. The study showed that olaparib monotherapy can produce prolonged disease stabilization in patients with grade 2/3 histology, but not in patients with grade 4 histology. This suggests potential clinical benefit of olaparib monotherapy in select populations.
CANCER RESEARCH COMMUNICATIONS
(2023)
Article
Biochemistry & Molecular Biology
Li-Ching Huang, Lindsey K. Stolze, Hua-Chang Chen, Alexander Gelbard, Yu Shyr, Qi Liu, Quanhu Sheng
Summary: Single-cell sequencing is widely used for studying cellular heterogeneity, and sample multiplexing is an important technique that allows for increased capacity, decreased costs, and minimized batch effects. The crucial step in analyzing multiplexed data is demultiplexing, which assigns cells to individual samples. Accurate demultiplexing is essential to avoid misleading characterization.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2023)
Article
Oncology
Derek A. Mumaw, Allison J. Hazy, Aleksander Vayntraub, Thomas J. Quinn, Kamran Salari, John H. Chang, Noah Kalman, Sanford Katz, James Urbanic, Robert H. Press, Arpi Thukral, Henry Tsai, George E. Laramore, Jason Molitoris, Carlos Vargas, Samir H. Patel, Craig Stevens, Rohan L. Deraniyagala
Summary: This study evaluated contralateral recurrences in patients with oropharyngeal squamous cell carcinoma who received unilateral proton beam therapy. The results showed a favorable contralateral neck failure rate that was comparable to photon irradiation.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Kangpyo Kim, Dongryul Oh, Jae Myoung Noh, Yang Won Min, Hong Kwan Kim, Yong Chan Ahn
Summary: This study suggests that hypofractionated radiation therapy alone is a feasible option for early stage esophageal squamous cell carcinoma patients. Particularly, in patients with tumor length < 3 cm, this treatment scheme shows favorable local control rates with low incidence of esophageal toxicities.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Lin Chen, Jing Li, Kunpeng Li, Jiang Hu, Qingjie Li, Chenglong Huang, Gaoyuan Wang, Na Liu, Linglong Tang
Summary: This study analyzed the probability of hearing impairment after radiotherapy for nasopharyngeal carcinoma and developed a predictive model, providing dose limitation suggestions to improve patients' quality of life.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Yiwei Yang, Jianxin Wang, Feng Gao, Zhen Liu, Tangzhi Dai, Haowen Zhang, Hongyu Zhu, Tingting Wang, Dexin Xiao, Kui Zhou, Zheng Zhou, Dai Wu, Xiaobo Du, Sen Bai
Summary: This paper provides a comprehensive description of the current status of PARTER, which is the first experimental FLASH platform utilizing megavoltage X-rays. It showcases the reliable performance and stability of the dosimeters and monitors used in PARTER, as well as the satisfactory dose distribution and characteristics of the FLASH X-rays. The platform effectively meets the requirements of preclinical research on megavoltage X-ray FLASH and undergoes continuous upgrades.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Maria Thor, Kelly Fitzgerald, Aditya Apte, Jung Hun Oh, Aditi Iyer, Otasowie Odiase, Saad Nadeem, Ellen D. Yorke, Jamie Chaft, Abraham J. Wu, Michael Offin, Charles B. Simone Ii, Isabel Preeshagul, Daphna Y. Gelblum, Daniel Gomez, Joseph O. Deasy, Andreas Rimner
Summary: The purpose of this study was to identify predictors of disease progression in early-stage non-small cell lung cancer (NSCLC) patients after receiving definitive stereotactic body radiation therapy (SBRT). The results showed that tumor diameter and SUVmax were the most frequently reported features associated with progression/survival, and a re-fitted model including these two features had the best performance.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Yong-Qiao He, Tong-Min Wang, Da-Wei Yang, Wen-Qiong Xue, Chang-Mi Deng, Dan-Hua Li, Wen-Li Zhang, Ying Liao, Ruo-Wen Xiao, Lu-Ting Luo, Hua Diao, Xia-Ting Tong, Yan-Xia Wu, Xue-Yin Chen, Jiang-Bo Zhang, Ting Zhou, Xi-Zhao Li, Pei-Fen Zhang, Xiao-Hui Zheng, Shao-Dan Zhang, Ye-Zhu Hu, Guan-Qun Zhou, Jun Ma, Ying Sun, Wei-Hua Jia
Summary: In this study, researchers aimed to establish a predictive model for radiation-induced brain injury (RBI) in nasopharyngeal carcinoma (NPC) patients by incorporating clinical factors and newly developed genetic variants. They conducted a large-scale retrospective study and a genome-wide association study to develop a polygenic risk score (PRS) for RBI risk prediction. The results showed that the PRS, combined with clinical factors, improved the accuracy of RBI risk stratification and suggested personalized radiotherapy.
RADIOTHERAPY AND ONCOLOGY
(2024)
Review
Oncology
Xiaoyong Xiang, Zhe Ji, Jing Jin
Summary: A review of studies suggests that brachytherapy as a salvage therapy for recurrent glioblastoma shows acceptable safety and good post-treatment clinical efficacy for selected patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
M. Berbee, C. T. Muijs, F. E. M. Voncken, L. Wee, M. Sosef, B. van Etten, J. W. van Sandick, F. A. R. M. Warmerdam, J. J. de Haan, E. Oldehinkel, J. M. van Dieren, L. Boersma, J. A. Langendijk, A. van der Schaaf, J. B. Reitsma, E. Schuit
Summary: This study externally validated a model for predicting 2-year total mortality in lung cancer patients in esophageal cancer patients. The intercept and/or slope of the original model needed adjustment to achieve good performance in esophageal cancer patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Dominique Reijtenbagh, Jeremy Godart, Joan Penninkhof, Sandra Quint, Andras Zolnay, Jan-Willem Mens, Mischa Hoogeman
Summary: This study compared the performance of the current PotD strategy with non-adaptive and fully online-adaptive techniques in the treatment of cervical cancer patients. The findings show that the PotD protocol is effective in improving normal tissue sparing compared to no adaptation, while fully online-adaptive approaches can further reduce target volume but come with a more complex workflow.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Albrecht Weiss, Steffen Loeck, Ting Xu, Zhongxing Liao, Aswin L. Hoffmann, Esther G. C. Troost
Summary: Traditional models for predicting radiation pneumonitis may not be applicable to non-small cell lung cancer patients treated with passively-scattered proton therapy. The use of effective alpha/beta parameter can predict the occurrence of radiation pneumonitis in these patients.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Z. A. R. Gouw, J. Jeong, A. Rimner, N. Y. Lee, A. Jackson, A. Fu, J-j. Sonke, J. O. Deasy
Summary: This study investigates the effectiveness of non-uniform fractionation schedules in radiotherapy for early-stage non-small cell lung cancer. Through modeling, optimized schedules are proposed to minimize local failures and toxicity risk. The results suggest that non-standard primer shot fractionation can reduce hypoxia-induced radioresistance and improve treatment outcomes.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Sara Ronchi, Alessandro Cicchetti, Maria Bonora, Rossana Ingargiola, Anna Maria Camarda, Stefania Russo, Sara Imparato, Paolo Castelnuovo, Ernesto Pasquini, Piero Nicolai, Mohssen Ansarin, Michele Del Vecchio, Marco Benazzo, Ester Orlandi, Barbara Vischioni
Summary: This study evaluates the efficacy and toxicity of carbon ion radiotherapy (CIRT) in locally advanced head and neck mucosal melanoma patients. The results show that CIRT is safe and effective in treating the local region, and immunotherapy after relapse can improve overall survival. However, further prospective trials are needed to assess the role of targeted/immune- systemic therapy in this disease.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Dominik Wawrzuta, Justyna Klejdysz, Marzanna Chojnacka
Summary: This study analyzed articles about radiation oncology published in The New York Times since its inception in 1851, and identified changes in media sentiment and prevalent themes related to radiotherapy. The findings suggest an increasing negative sentiment in media coverage towards radiotherapy, with a shift towards reporting treatment errors, toxicity, and ineffectiveness.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Elaine Limkin, Pierre Blanchard, Benjamin Lacas, Jean Bourhis, Mahesh Parmar, Lisa Licitra, Quynh-Thu Le, Sue S. Yom, Catherine Fortpied, Johannes Langendijk, Jan B. Vermorken, Jacques Bernier, Jens Overgaard, Jonathan Harris, Jean-Pierre Pignon, Anne Auperin
Summary: This study investigated the impact of season of radiotherapy on the outcomes of head and neck squamous cell cancer patients. The results showed that the season of radiotherapy did not have any significant effect on patient outcomes.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Fabio L. Cury, Gustavo A. Viani, Andre G. Gouveia, Camila V. S. Freire, Gabriel de A. Grisi, Fabio Y. Moraes
Summary: In limb-sparing treatment of soft tissue sarcoma patients, a 5-day course of preoperative radiotherapy results in high local control and favorable R0 margins, with acceptable complication rates, particularly for patients receiving higher biological equivalent doses.
RADIOTHERAPY AND ONCOLOGY
(2024)